PVLA

#1926
Palvella Therapeutics, Inc. - Common Stock
154.7 3 USD
0.00%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
154.47
155.36
Jahresspanne
68.96
161.38
Tagesänderung
-0.48%
Monatliche Änderung
-0.33%
6 month change
+19.46%
Jahresänderung
+109.52%
Vorheriger Schlusskurs
155.4 7
Open
154.8 3
Tief
154.4 7
Hoch
155.3 6
Volumen
39
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
PALVELLA THERAPEUTICS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
PALVELLA THERAPEUTICS, INC. current report, Q2 FY2026
8-K

PALVELLA THERAPEUTICS, INC. current report, Q3 FY2026

Full document

Business Context and Reporting Period

Company: Palvella Therapeutics, Inc. (PVLA)
Filing Type: Form 8-K (Current Report)
Report Date: August 4, 2026
Reporting Period: Quarter ended June 30, 2026
Context: The filing announces the release of financial results for the second quarter of 2026 and the scheduling of an earnings call. The detailed financial data is contained in a press release (Exhibit 99.1) and an earnings presentation (Exhibit 99.2) furnished with this report.

Key Financial Metrics

The provided text is a cover sheet for the Form 8-K and does not contain specific numerical data. The filing explicitly states that the detailed financial results are incorporated by reference in Exhibit 99.1.

  • Revenue: Not provided in the filing text.
  • Profit/Loss: Not provided in the filing text.
  • Cash Flow: Not provided in the filing text.
  • Margins: Not provided in the filing text.
  • Debt and Liquidity: Not provided in the filing text.

Material Changes

The filing text does not provide specific comparative data or material changes versus the prior period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year or quarter-over-quarter analysis.

Guidance, Outlook, and Risks

Management Commentary: The Company announced it will hold an earnings call on August 4, 2026, utilizing a slide presentation (Exhibit 99.2) to discuss the results.
Legal Status of Information: The information furnished under Item 2.02 and Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference into other filings unless expressly stated.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for the quarter ended June 30, 2026.
  • Examine Exhibit 99.2 (Earnings Presentation) for management's outlook, pipeline updates, and guidance.
  • Verify the date and time of the earnings call to access real-time management commentary.
  • Confirm the company's cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical company but are not listed in the 8-K cover text.